Eckardt J R, Von Hoff D D
University of Texas Health Science Center, San Antonio.
Hematol Oncol Clin North Am. 1994 Apr;8(2):305-32.
Over the past few years, a number of new antineoplastic agents have reached the clinical arena. These agents have demonstrated activity in a wide variety of preclinical tumor models and many have been found to have novel mechanisms of action. Some of these new agents are now in Phase I and Phase II trials demonstrating antitumor activity and unique toxicity profiles. In this article, the authors review some of the new agents in clinical development in the United States.
